Gland Pharma shares surged 4% after receiving USFDA approval for its Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules. This product is a generic equivalent to Hospira Inc.’s Vitamin K1 Injectable Emulsion and addresses coagulation disorders caused by vitamin K deficiency or interference with its activity.
With the US market reporting sales of approximately $15 million for this product over the 12 months ending September 2024, the approval positions Gland Pharma for a lucrative launch through its marketing partners.
Gland Pharma shares opened at ₹1,850 today, reaching a high of ₹1,864 and a low of ₹1,821 during trading. The stock remains well below its 52-week high of ₹2,220.95 but above the 52-week low of ₹1,585.70.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
